Next generation cancer immunotherapies
Targeting
non-conventional antigens
to reshape tumor immunity
The sense of advertising changes every day, so don’t wait and check
what our agency can offer your company now!
Vision & Mission
Combining cancer vaccines
and T-cell therapies
ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.
We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).
Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.
recent news
From the blog
Notre tour de France #5
De Brest à Marseille, nous avons décidé d’aller à la rencontre de nos clients.
Notre tour de France #4
De Brest à Marseille, nous avons décidé d’aller à la rencontre de nos clients.
Notre tour de France #3
De Brest à Marseille, nous avons décidé d’aller à la rencontre de nos clients.
recent files
Publications & abstracts
Faites du slip !
Logo + E-Commerce + Print
La Crevette Bleue
Logo + E-Commerce + Print
inesti Patrimoine
Naming + Logo + Site Internet + Print
About ErVimmune
Medical research and development, in particular the development of new families of tumour antigens.
Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.
Read more
Useful links
> Publications & abstracts
> Recent news
> Vision & Mission
Navigation
> home
> about us
> Sciences
> Investors
> Join us
> Contact
Contact infos
28 RUE LAENNEC
69008
LYON FRANCE
contact@ervimmune.com
+33 6 67 67 44 97
© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go